Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762713 | 0.89 | ALDH1A1 (0.50) | SLC22A12ALDH1A1PKMAR | |
| SCHEMBL5860349 | 0.84 | AR (0.42) | PKMAR | |
| SCHEMBL5761786 | 0.83 | PKM (0.52) | PKMPPARGAR | |
| SCHEMBL5761510 | 0.80 | FFAR1 (0.51) | KMT2APKMPPARGAR | |
| SCHEMBL5759527 | 0.80 | SLC40A1 (0.56) | ALDH1A1KMT2A | |
| SCHEMBL5759800 | 0.80 | HTT (0.50) | PKMAR | |
| SCHEMBL5823524 | 0.80 | AR (0.46) | PKMAR | |
| SCHEMBL5759592 | 0.80 | AR (0.47) | PKMAR | |
| SCHEMBL5760654 | 0.79 | LMNA (0.48) | PKMAR | |
| SCHEMBL5761661 | 0.79 | CLK1 (0.52) | ALDH1A1KMT2APKMAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | claimed |
| EP-1633732-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | claimed |
| WO-2004101544-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-25 | — | — | WO | claimed |
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137228-A1 | Benzyl sulfonamide derivatives | AR, SHBG, BRDT | SLC22A12 1909/4885ALPL 4582/4885KDM4E 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.